CETYLEV

Peak

acetylcysteine

NDAORALTABLET, EFFERVESCENT
Approved
Jan 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
19

Mechanism of Action

overdose. Acetaminophen doses of 150 mg/kg or greater have been associated with hepatotoxicity. Acetylcysteine probably protects the liver by maintaining or restoring the glutathione levels, or by acting as an alternate substrate for conjugation with, and thus detoxification of, the reactive…

Clinical Trials (5)

NCT05070650Phase 3Withdrawn

Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold

Started Sep 2024
0
Common Cold
NCT05241262Phase 1Recruiting

Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels

Started Jul 2023
18 enrolled
Mitochondrial Disease
NCT04481048Phase 2Active Not Recruiting

Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1

Started Dec 2020
58 enrolled
Neurofibromatosis 1
NCT04123405Phase 3Completed

Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis

Started Oct 2020
944 enrolled
Rhinosinusitis
NCT04419025Phase 2Completed

Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease

Started Sep 2020
165 enrolled
COVIDSars-CoV2SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere+1 more

Loss of Exclusivity

LOE Date
May 8, 2032
75 months away
Patent Expiry
May 8, 2032

Patent Records (3)

Patent #ExpiryTypeUse Code
8747894
May 8, 2032
Product
U-1373
9427421
May 8, 2032
Product
9561204
May 8, 2032
U-1373